Collaborative Arrangements (Tables)

3 Months Ended

Mar. 31, 2013

During the three months ended March 31, 2013 and 2012, the Company recognized the following revenues attributable to the Janssen collaboration:



	Three Months Ended March 31,
	2013			2012
	(in thousands)
Royalty revenues	$	39,044		$	32,884
Collaborative revenues:
Amortized portion of up-front payment	$	3,107		$	3,107
Net reimbursement (payment) for telaprevir development costs	(27		)	(1,139		)
Reimbursement for manufacturing services	10,299			4,449
Total collaborative revenues attributable to the Janssen collaboration	$	13,379		$	6,417
Total revenues attributable to the Janssen collaboration	$	52,423		$	39,301

A summary of net loss (income) attributable to noncontrolling interest (Alios) for the three months ended March 31, 2013 and 2012, is as follows:



	Three Months Ended March 31,
	2013			2012
	(in thousands)
Loss (income) before provision for (benefit from) income taxes	$	5,297		$	5,024
Decrease (increase) in fair value of contingent milestone and royalty payments	2,740			970
Provision for (benefit from) income taxes	(3,426		)	(2,280		)
Net loss (income) attributable to noncontrolling interest (Alios)	$	4,611		$	3,714

The following table summarizes items related to Alios included in the Company’s condensed consolidated balance sheets:



	As of March 31, 2013		As of December 31, 2012
	(in thousands)
Restricted cash and cash equivalents (Alios)	$	63,008	$	69,983
Prepaid expenses and other current assets	3,776		672
Property and equipment, net	1,623		1,728
Intangible assets	250,600		250,600
Goodwill	4,890		4,890
Other assets	990		861
Accounts payable	1,975		1,054
Accrued expenses	5,019		6,099
Deferred tax liability	151,664		152,781
Other liabilities, excluding current portion	648		1,625
Redeemable noncontrolling interest (Alios)	38,872		38,530
Noncontrolling interest (Alios)	191,845		196,672